Current Report Filing (8-k)
July 26 2017 - 6:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): July 21, 2017
SECOND SIGHT MEDICAL PRODUCTS, INC.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
California
|
(State or Other Jurisdiction of Incorporation)
|
|
333-198073
|
|
|
02-0692322
|
|
|
(Commission File Number)
|
|
|
(IRS Employer Identification No.)
|
|
|
12744 San Fernando Road, Suite 400
Sylmar, California 91342
|
|
(Address of Principal Executive Offices)
|
|
(818) 833-5000
|
(Registrant’s Telephone Number, Including Area Code)
|
|
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
July 21, 2017, the Compensation Committee of the Board of Directors of Second Sight Medical Products, Inc. (the “Company”)
approved by written consent the following adjustments to the compensation of the executive officers of the Company to become effective
as of July 1, 2017:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual
|
|
|
|
|
|
Adjusted
|
Name
|
|
Position
|
|
Base
|
|
%
Raise
|
|
$
Raise
|
|
Base
|
|
|
|
|
|
|
|
|
|
|
|
Will
McGuire
|
|
President
and Chief Executive Officer
|
|
$
|
394,000
|
|
|
|
3.5
|
%
|
|
$
|
13,790
|
|
|
$
|
407,790
|
|
Robert
J. Greenberg, M.D., Ph.D.
|
|
Chairman
of the Board
|
|
$
|
438,000
|
|
|
|
1.5
|
%
|
|
$
|
6,570
|
|
|
$
|
444,570
|
|
Thomas
B. Miller
|
|
Chief
Financial Officer
|
|
$
|
281,000
|
|
|
|
2.0
|
%
|
|
$
|
5,620
|
|
|
$
|
286,620
|
|
Steve
Okland
|
|
Commercial
Vice President, U.S. and Canada
|
|
$
|
260,000
|
|
|
|
3.0
|
%
|
|
$
|
7,800
|
|
|
$
|
267,800
|
|
Gregoire
Cosendai
(1)
|
|
Vice
President of European Operations
|
|
$
|
256,684
|
|
|
|
2.0
|
%
|
|
$
|
5,134
|
|
|
$
|
261,818
|
|
Edward
Randolph
|
|
Vice President of Operations, Quality
Assurance and Information Technology
|
|
$
|
244,000
|
|
|
|
2.0
|
%
|
|
$
|
4,880
|
|
|
$
|
248,880
|
|
1.
Converted from Swiss Francs into U.S. Dollars at a conversion rate of $1.05 per one Swiss Franc.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
July 25, 2017
SECOND
SIGHT MEDICAL PRODUCTS, INC.
By:
Thomas B. Miller
Chief
Financial Officer
-3-
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Aug 2024 to Sep 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Sep 2023 to Sep 2024